Killed oral cholera vaccines: from concept to public health reality  by Clemens, J.
al of I
T
F
S
D
T
R
T
a
S
S
1
N
2
t
s
i
a
d
i
d
i
a
s
f
i
t
t
w
A
t
i
a
f
4
t
(
a
O
h
a
o
g
p
d
i
v
v
h
available oral cholera vaccine, this vaccine should add signiﬁcantly
to current efforts to control cholera among the world’s poor.
http://dx.doi.org/10.1016/j.ijid.2012.05.04015th ICID Abstracts / International Journ
ype: Oral Presentation
inal Abstract Number: 07.010
ession: Disease Surveillance
ate: Thursday, June 14, 2012
ime: 10:15-12:15
oom: Lotus 11
ravellers contribute largely to the epidemiology of inﬂuenza:
prospective study
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etherlands
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Background: Inﬂuenza is highly infectious with a short incuba-
ion period. Travel therefore, can play an important role in the rapid
pread of inﬂuenza.We prospectively assessed the attack rate (AR),
ncidence rate (IR) and risk factors for inﬂuenza virus infections
mong travellers.
Methods: Persons attending a travel clinic in 2006/2007 before
eparting on short-term travel to developing countries, were
nvited to participate. Participants kept a structured daily travel
iary and donated blood samples before and after travel for
nﬂuenza serology using the hemagglutination-inhibition (HI)
ssay. Four vaccine strains representing the circulating epidemic
trains, were used. If post-travel titre for inﬂuenza showed a ≥4-
old increaseabovepre-travel titre, thiswasconsideredaconﬁrmed
nﬂuenza infection for the inﬂuenza type tested. Patients with pre-
ravel titres ≥40 were considered immune.
Results:Of 1190 respondents, 87%were born in awestern coun-
ry, 43% were male and median age was 37. Median travel duration
as 21 days. 46% travelled to Asia; 27% to Latin America and 24% to
frica. The AR of laboratory conﬁrmed inﬂuenzawas 7.2% (86/1190
ravellers), the IR 8.9/100 person-months. The AR of symptomatic
nfection was 1.4%; the IR 2.0/100 person-months. South-Central
ndWest Asia showed the highest AR and incidence rate ratio (IRR)
or symptomatic and asymptomatic infection. The age-groups 35-
4 years and 55-64 years had signiﬁcantly higher IRR’s compared
o the age-group <25 years (IRR 2.6 (95%CI:1.1-5.9) and IRR 2.9
95%CI:1.2-6.7) respectively). Being born in a non-western country
nd having symptoms were independent risk factors for infection.
f all 1190 travellers 161 (13.5%) had fever, of whom 17 (10.6%)
ad conﬁrmed inﬂuenza. Ten of 17 (59%) sought medical attention
broad. No hospitalisations due to inﬂuenza were recorded. Half
f travellers with symptomatic infection were considered conta-
ious or incubatingwhile travelling home. All conﬁrmed caseswith
re-existing immunity were asymptomatic.
Conclusion: Inﬂuenza is a frequently acquired infectious travel
isease. Half of the symptomatic travellers could have imported the
nfection to the Netherlands. Annually 2 million Dutch travellers
isit developing countries, therefore an estimated 13.000 inﬂuenza
iruses could be imported each year.
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Modern biotechnology is yielding an enormous diversity of new
vaccine candidates that offer breathtaking prospects for disease
prevention in developing countries. However, at times the focus on
new vaccines and new technologies has diverted attention away
from considering already licensed vaccines that could be useful
disease-control tools in developing countries. A good example is
killed, orally administered cholera vaccines consisting of inacti-
vated cholera whole cells (WC), with or without cholera toxin B
subunit (BS). Despite evidence of the safety and protection con-
ferred by these vaccines, their use in public health programs for
the poor has been limited. An internationally licensed recombi-
nant (rBS-WC) vaccine has been available for nearly 20 years, but
its use has been restricted to travelers, largely because of its cost.
On the other hand, an inexpensive WC-only vaccine produced in
Vietnam has been used in public health programs in that country,
but not in other cholera-endemic countries due to the facts that
it is not currently being produced according to cGMP and that the
National Regulatory Authority (NRA) of Vietnam is not approved by
the World Health Organization (WHO). A team at the International
Vaccine Institute (IVI),with support fromtheBill andMelindaGates
Foundation, worked with the Vietnamese producer (VaBiotech) to
bring the production of the vaccine to international standards. The
IVI team redesigned the Vietnamese vaccine, its production meth-
ods, and quality control tests to meet WHO standards. Moreover,
to make this new vaccine internationally acceptable, the IVI team
transferred this newly redesignedWC-only vaccine to aproducer in
India (Shantha Biotechnics), where the NRA is WHO-approved. The
IVI team designed and conducted a clinical development program
for licensure of this vaccine in both Vietnam and India, culminat-
ing in a Phase 3 trial in Kolkata, conducted in collaboration with
the National Institute of Cholera and Enteric Diseases in ca. 70,000
persons, which found ca. 70% protection lasting at least 3 years.
This redesigned vaccine has now been licensed in both India and
Vietnam. As well, the vaccine has been prequaliﬁed by the WHO
for international use. As the world’s ﬁrst low-cost, internationally
